Biomarkers in the clinical development of asthma therapies

Biomarkers in Medicine

Volumn 10, Issue 2, 2016, Pages 165-176

  Staton, Tracy L ^a   Choy, David F ^a   Arron, Joseph R ^a  

^a GENENTECH INC   (United States)

Author keywords

AMG 317; asthma; benralizumab; biomarkers; brodalumab; dupilumab; eosinophils; FeNO; golilumab; GSK679586; lebrikizumab; mepolizumab; omalizumab; patient selection; periostin; pharmacodynamics; reslizumab; tralokinumab

Indexed keywords

AMG 317; BENRALIZUMAB; BRODALUMAB; DUPILUMAB; GOLIMUMAB; GSK 679586; IMMUNOGLOBULIN E; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 17F; INTERLEUKIN 4; INTERLEUKIN 4 RECEPTOR ALPHA; INTERLEUKIN 5; INTERLEUKIN 5 RECEPTOR; LEBRIKIZUMAB; MEPOLIZUMAB; MONOCLONAL ANTIBODY; OMALIZUMAB; PLACEBO; RESLIZUMAB; TRALOKINUMAB; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANTIASTHMATIC AGENT; INTERLEUKIN DERIVATIVE; PHARMACOLOGICAL BIOMARKER;

ASTHMA; DISEASE EXACERBATION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; FORCED EXPIRATORY VOLUME; HUMAN; REVIEW; SYMPTOM; BLOOD; INFLAMMATION; METABOLISM; MOLECULARLY TARGETED THERAPY; PHASE 2 CLINICAL TRIAL (TOPIC); SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ANTI-ASTHMATIC AGENTS; ANTIBODIES, MONOCLONAL; ASTHMA; BIOMARKERS, PHARMACOLOGICAL; CLINICAL TRIALS, PHASE II AS TOPIC; HUMANS; INFLAMMATION; INTERLEUKINS; MOLECULAR TARGETED THERAPY; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84961382219     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.15.116     Document Type: Review

References (76)

1. Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questions. American Thoracic Society. Am. J. Respir. Crit. Care Med. 162(6), 2341-2351 (2000).
2. Barnes PJ. Severe asthma: advances in current management and future therapy. J. Allergy Clin. Immunol. 129(1), 48-59 (2012).
3. Fajt ML, Wenzel SE. Asthma phenotypes and the use of biologic medications in asthma and allergic disease: the next steps toward personalized care. J. Allergy Clin. Immunol. 135(2), 299-310; quiz 311 (2015).
4. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 69(3), 89-95 (2001).
5. Arron JR, Scheerens H, Matthews JG. Redefining approaches to asthma: developing targeted biologic therapies. Adv. Pharmacol. 66, 1-49 (2013).
6. Shih H. Discovery process for antibody-based therapeutics. In: Development of Antibody-Based Therapeutics. Tabrizi MA, Bornstein GG, Klakamp SL (Eds). Springer, NY, USA, 9-32 (2012).
7. O'byrne PM. Allergen-induced airway inflammation and its therapeutic intervention. Allergy Asthma Immunol. Res. 1(1), 3-9 (2009).
8. Hayes D Jr, Kraman SS. The physiologic basis of spirometry. Respir. Care 54(12), 1717-1726 (2009).
9. Reddel HK, Taylor DR, Bateman ED et al. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am. J. Respir. Crit. Care Med. 180(1), 59-99 (2009).
10. Juniper EF, O'Byrne PM, Guyatt GH, Ferrie PJ, King DR. Development and validation of a questionnaire to measure asthma control. Eur. Respir. J. 14(4), 902-907 (1999).
11. Juniper EF, Svensson K, Mork AC, Stahl E. Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. Respir. Med. 99(5), 553-558 (2005).
12. Juniper EF, Guyatt GH, Willan A, Griffith LE. Determining a minimal important change in a disease-specific Quality of Life Questionnaire. J. Clin. Epidemiol. 47(1), 81-87 (1994).
13. Bel EH, Wenzel SE, Thompson PJ et al. Oral glucocorticoidsparing effect of mepolizumab in eosinophilic asthma. N. Engl. J. Med. 371(13), 1189-1197 (2014).
14. Nair P, Pizzichini MM, Kjarsgaard M et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N. Engl. J. Med. 360(10), 985-993 (2009).
15. Castro M, Zangrilli J, Wechsler ME et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, Phase 3 trials. Lancet Respir. Med. 3(5), 355-366 (2015).
16. Ortega HG, Liu MC, Pavord ID et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N. Engl. J. Med. 371(13), 1198-1207 (2014).
17. Castro M, Wenzel SE, Bleecker ER et al. Benralizumab, an anti-interleukin 5 receptor alpha monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a Phase 2b randomised dose-ranging study. Lancet Respir. Med. 2(11), 879-890 (2014).
18. Corren J, Lemanske RF, Hanania NA et al. Lebrikizumab treatment in adults with asthma. N. Engl. J. Med. 365(12), 1088-1098 (2011).
19. Chipps BE, Zeiger RS, Borish L et al. Key findings and clinical implications from The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) study. J. Allergy Clin. Immunol. 130(2), 332-342. e310 (2012).
20. Hanania NA, Wenzel S, Rosen K et al. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am. J. Respir. Crit. Care Med. 187(8), 804-811 (2013).
21. Artis D, Spits H. The biology of innate lymphoid cells. Nature 517(7534), 293-301 (2015).
22. Galli SJ, Tsai M, Piliponsky AM. The development of allergic inflammation. Nature 454(7203), 445-454 (2008).
23. Laporte SL, Juo ZS, Vaclavikova J et al. Molecular and structural basis of cytokine receptor pleiotropy in the interleukin-4/13 system. Cell 132(2), 259-272 (2008).
24. Goenka S, Kaplan MH. Transcriptional regulation by STAT6. Immunol. Res. 50(1), 87-96 (2011).
25. Lebman DA, Coffman RL. Interleukin 4 causes isotype switching to IgE in T cell-stimulated clonal B cell cultures. J. Exp. Med. 168(3), 853-862 (1988).
26. Holgate S, Buhl R, Bousquet J, Smith N, Panahloo Z, Jimenez P. The use of omalizumab in the treatment of severe allergic asthma: a clinical experience update. Respir. Med. 103(8), 1098-1113 (2009).
27. Nagarkar DR, Ramirez-Carrozzi V, Choy DF et al. IL-13 mediates IL-33-dependent mast cell and type 2 innate lymphoid cell effects on bronchial epithelial cells. J. Allergy Clin. Immunol. 136(1), 202-205 (2015).
28. Hoeck J, Woisetschlager M. Activation of eotaxin-3/CCLl26 gene expression in human dermal fibroblasts is mediated by STAT6. J. Immunol. 167(6), 3216-3222 (2001).
29. Jia G, Erickson RW, Choy DF et al. Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients. J. Allergy Clin. Immunol. 130(3), 647-654, e610 (2012).
30. Arron JR, Choy DF, Scheerens H, Matthews JG. Noninvasive biomarkers that predict treatment benefit from biologic therapies in asthma. Ann. Am. Thorac. Soc. 10(Suppl.), S206-S213 (2013).
31. Woodruff PG, Boushey HA, Dolganov GM et al. Genomewide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroids. Proc. Natl Acad. Sci. USA 104(40), 15858-15863 (2007).
32. Modena BD, Tedrow JR, Milosevic J et al. Gene expression in relation to exhaled nitric oxide identifies novel asthma phenotypes with unique biomolecular pathways. Am. J. Respir. Crit. Care Med. 190(12), 1363-1372 (2014).
33. Ultsch M, Bevers J, Nakamura G et al. Structural basis of signaling blockade by anti-IL-13 antibody Lebrikizumab. J. Mol. Biol. 425(8), 1330-1339 (2013).
34. Hanania NA, Noonan M, Corren J et al. Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies. Thorax 70(8), 748-756 (2015).
35. Heleen S, Joseph RA, David FC, Sofia M, Preeti L, John GM. Lebrikizumab treatment reduces serum periostin levels in asthma patients with elevated baseline levels of periostin. In: C22. ASTHMA THERAPY, American Thoracic Society, A3960-A3960 (2012).
36. Piper E, Brightling C, Niven R et al. A Phase II placebocontrolled study of tralokinumab in moderate-to-severe asthma. Eur. Respir. J. 41(2), 330-338 (2013).
37. Christopher EB, Dewei S, Koustubh R, Edward P. Efficacy and safety of tralokinumab, an anti-IL-13 monoclonal antibody, in a Phase 2b study of uncontrolled severe asthma. In: C30. Late Breaking Abstracts In Disease Treatment And Clinical Outcomes. American Thoracic Society, A6670-A6670 (2014).
38. Hodsman P, Ashman C, Cahn A et al. A Phase 1, randomized, placebo-controlled, dose-escalation study of an anti-IL-13 monoclonal antibody in healthy subjects and mild asthmatics. Br. J. Clin. Pharmacol. 75(1), 118-128 (2013).
39. De Boever EH, Ashman C, Cahn AP et al. Efficacy and safety of an anti-IL-13 mAb in patients with severe asthma: a randomized trial. J. Allergy Clin. Immunol. 133(4), 989-996 (2014).
40. Wenzel S, Ford L, Pearlman D et al. Dupilumab in persistent asthma with elevated eosinophil levels. N. Engl. J. Med. 368(26), 2455-2466 (2013).
41. Corren J, Busse W, Meltzer EO et al. A randomized, controlled, Phase 2 study of AMG 317, an IL-4Ralpha antagonist, in patients with asthma. Am. J. Respir. Crit. Care Med. 181(8), 788-796 (2010).
42. Molfino NA, Gossage D, Kolbeck R, Parker JM, Geba GP. Molecular and clinical rationale for therapeutic targeting of interleukin-5 and its receptor. Clin. Exp. Allergy 42(5), 712-737 (2012).
43. Leckie MJ, Ten Brinke A, Khan J et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 356(9248), 2144-2148 (2000).
44. Flood-Page PT, Menzies-Gow AN, Kay AB, Robinson DS. Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am. J. Respir. Crit. Care Med. 167 (2), 199-204 (2003).
45. Menzies-Gow AN, Flood-Page PT, Robinson DS, Kay AB. Effect of inhaled interleukin-5 on eosinophil progenitors in the bronchi and bone marrow of asthmatic and nonasthmatic volunteers. Clin. Exp. Allergy 37(7), 1023-1032 (2007).
46. Yamada T, Sun Q, Zeibecoglou K et al. IL-3, IL-5, granulocyte-macrophage colony-stimulating factor receptor alpha-subunit, and common beta-subunit expression by peripheral leukocytes and blood dendritic cells. J. Allergy Clin. Immunol. 101(5), 677-682 (1998).
47. Haldar P, Brightling CE, Hargadon B et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N. Engl. J. Med. 360(10), 973-984 (2009).
48. Pavord ID, Korn S, Howarth P et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 380(9842), 651-659 (2012).
49. Prazma CM, Wenzel S, Barnes N, Douglass JA, Hartley BF, Ortega H. Characterisation of an OCS-dependent severe asthma population treated with mepolizumab. Thorax 69(12), 1141-1142 (2014).
50. Castro M, Mathur S, Hargreave F et al. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am. J. Respir. Crit. Care Med. 184(10), 1125-1132 (2011).
51. Gevaert P, Lang-Loidolt D, Lackner A et al. Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps. J. Allergy Clin. Immunol. 118(5), 1133-1141 (2006).
52. Busse WW, Katial R, Gossage D et al. Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a Phase I study of subjects with mild asthma. J. Allergy Clin. Immunol. 125(6), 1237.e1232-1244.e1232 (2010).
53. Laviolette M, Gossage DL, Gauvreau G et al. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. J. Allergy Clin. Immunol. 132(5), 1086.e1085-1096.e1085 (2013).
54. Eck S, Castro M, Sinibaldi D et al. Benralizumab effect on blood basophil counts in adults with uncontrolled asthma. Eur. Respir. J. 44(Suppl. 58), CN-01053403 (2014).
55. Fahy JV. Eosinophilic and neutrophilic inflammation in asthma: insights from clinical studies. Proc. Am. Thorac. Soc. 6(3), 256-259 (2009).
56. Al-Ramli W, Prefontaine D, Chouiali F et al. T(H)17-associated cytokines (IL-17A and IL-17F) in severe asthma. J. Allergy Clin. Immunol. 123(5), 1185-1187 (2009).
57. Berry MA, Hargadon B, Shelley M et al. Evidence of a role of tumor necrosis factor alpha in refractory asthma. N. Engl. J. Med. 354(7), 697-708 (2006).
58. Goleva E, Hauk PJ, Hall CF et al. Corticosteroid-resistant asthma is associated with classical antimicrobial activation of airway macrophages. J. Allergy Clin. Immunol. 122(3), 550-559.e553 (2008).
59. Miossec P, Kolls JK. Targeting IL-17 and TH17 cells in chronic inflammation. Nat. Rev. Drug Discov. 11(10), 763-776 (2012).
60. Miossec P, Korn T, Kuchroo VK. Interleukin-17 and type 17 helper T cells. N. Engl. J. Med. 361(9), 888-898 (2009).
61. Aggarwal BB. Signalling pathways of the TNF superfamily: a double-edged sword. Nat. Rev. Immunol. 3(9), 745-756 (2003).
62. Ito T, Wang YH, Duramad O et al. TSLP-activated dendritic cells induce an inflammatory T helper type 2 cell response through OX40 ligand. J. Exp. Med. 202(9), 1213-1223 (2005).
63. Thomas PS, Heywood G. Effects of inhaled tumour necrosis factor alpha in subjects with mild asthma. Thorax 57(9), 774-778 (2002).
64. Hueber W, Patel DD, Dryja T et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci. Transl. Med. 2(52), 52ra72 (2010).
65. Mcinnes IB, Sieper J, Braun J et al. Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, Phase II proof-of-concept trial. Ann. Rheum. Dis. 73(2), 349-356 (2014).
66. Palladino MA, Bahjat FR, Theodorakis EA, Moldawer LL. Anti-TNF-alpha therapies: the next generation. Nat. Rev. Drug Discov. 2(9), 736-746 (2003).
67. Papp KA, Leonardi C, Menter A et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N. Engl. J. Med. 366(13), 1181-1189 (2012).
68. Russell CB, Rand H, Bigler J et al. Gene expression profiles normalized in psoriatic skin by treatment with brodalumab, a human anti-IL-17 receptor monoclonal antibody. J. Immunol. 192(8), 3828-3836 (2014).
69. Busse WW, Holgate S, Kerwin E et al. Randomized, doubleblind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma. Am. J. Respir. Crit. Care Med. 188(11), 1294-1302 (2013).
70. Papp K, Leonardi C, Menter A et al. Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment. J. Am. Acad. Dermatol. 71(6), 1183-1190, e1183 (2014).
71. Morjaria JB, Chauhan AJ, Babu KS, Polosa R, Davies DE, Holgate ST. The role of a soluble TNFalpha receptor fusion protein (etanercept) in corticosteroid refractory asthma: a double blind, randomised, placebo controlled trial. Thorax 63(7), 584-591 (2008).
72. Howarth PH, Babu KS, Arshad HS et al. Tumour necrosis factor (TNFalpha) as a novel therapeutic target in symptomatic corticosteroid dependent asthma. Thorax 60(12), 1012-1018 (2005).
73. Wenzel SE, Barnes PJ, Bleecker ER et al. A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma. Am. J. Respir. Crit. Care Med. 179(7), 549-558 (2009).
74. Dennis G Jr, Holweg CT, Kummerfeld SK et al. Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics. Arthritis Res. Ther. 16(2), R90 (2014).
75. Djukanovic R, Wilson SJ, Kraft M et al. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am. J. Respir. Crit. Care Med. 170(6), 583-593 (2004).
76. Scheerens H, Arron JR, Zheng Y et al. The effects of lebrikizumab in patients with mild asthma following whole lung allergen challenge. Clin. Exp. Allergy 44(1), 38-46 (2014).